This study is testing if adding a drug called durvalumab (an immunotherapy) to the standard treatment of chemotherapy and radiation helps people with limited-stage small cell lung cancer live longer without their cancer getting worse. About 105 participants will be randomly assig…
Phase: PHASE2 • Sponsor: Michael Hopp • Aim: Disease control
Last updated Apr 02, 2026 10:57 UTC